Full Court warns against dangerous affliction of parameteritis (and confirms invalidity of aripiprazole patent)
26 August 2016
On Wednesday the Full Court of the Federal Court of Australia handed down a decision in which it upheld Justice Yates’ findings that Otsuka’s patent relating to aripiprazole, a drug used in the treatment of schizophrenia, is invalid for want of novelty and inventive step. Otsuka had alleged that Generic Health’s aripiprazole products, which were registered for the treatment of schizophrenia, infringed the patent.
Read on